Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
Tubulin inhibitors by themselves can limit tumor growth, and they can be particularly effective when conjugated to monoclonal antibodies that target them to tumors. Two such conjugates, trastuzumab emtansine and brentuximab vedotin, have been approved by the FDA. However, many cancers can develop resistance to such inhibitors, highlighting the need for next-generation compounds.
Recent evidence suggests the gastrin/cholecystokinin-2 receptor (CCK2R) is a potential target for radiolabeled theranostics in cancer, but the stability of minigastrin analogues remains unresolved. Researchers from the National University of Singapore aimed to develop a peptide with improved tumor uptake and prolonged retention in CCK2R+ cancers.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Activating Toll-like receptors (TLRs) with agonists can promote pro-inflammatory responses mediated by the adaptor protein MyD88 and the downstream effector NF-κB, and these responses can inhibit tumor growth.
Sichuan Biokin Pharmaceutical Co. Ltd. has gained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with [177Lu]-BL-ARC001 injection.
RSS
